How to buy Cara Therapeutics shares | US$17.54

Own your own CARA stock in just a few minutes.

Posted

Fact checked

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

US$17.54
current price
US$0.01
change
0.057%
change %

How to buy stock in Cara Therapeutics

  1. Compare share trading platforms. To buy shares in a US company from New Zealand you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cara Therapeutics. Find the share by name or ticker symbol: CARA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cara Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$17.54, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Cara Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cara Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
  7. Price details for Cara Therapeutics (CARA)

    Open $17.47 Previous close $17.53
    High $17.9691 Change $0.01
    Low $16.91 Change % 0.057%
    Close $17.54 Timestamp 1594756800
    Volume N/A GMT offset 0

    Cara Therapeutics stock price

    Use our graph to track the performance of CARA stocks over time.

    Compare share trading platforms

    Data indicated here is updated regularly
    Name Product Monthly fee Currency conversion fee Available markets
    Stake
    $0
    1% ($2 min)
    NASDAQ
    NYSE
    BATS
    Chicago Stock Exchange
    And more
    Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade 3,500 US listed stocks and ETFs through Stake with $0 brokerage.
    loading

    Compare up to 4 providers

    The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

    Cara Therapeutics company summary

    Information last updated 2020-07-12.

    Cara Therapeutics (CARA) is a leading Pharmaceuticals business based in the USA. Cara Therapeutics (CARA) is listed on the NASDAQ and employs 67 staff.

    Profile

    Industry Biotechnology Currency symbol $
    Code CARA Country name USA
    Type Common Stock Country ISO US
    Name Cara Therapeutics, Inc ISIN US1407551092
    Exchange NASDAQ CUSIP 140755109
    Currency code USD Sector Healthcare
    Currency name US Dollar Full-time employees 67

    Detailed company information

    Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Go to site